CoChat

Serum FGF21 levels in adult m.3243A>G carriers: Clinical implications

Koene, Saskia, de Laat, Paul, van Tienoven, Doorlène H., Vriens, Dennis, Brandt, André M., Sweep, Fred C.G.J., Rodenburg, Richard J.T., Donders, A. Rogier T., Janssen, Mirian C.H., Smeitink, Jan A.M. · 2014 · Neurology
Cited by 39

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: To determine the value of fibroblast growth factor 21 (FGF21), a recently discovered biomarker for mitochondrial disease, in predicting clinical disease severity and disease progression in adult carriers of the m.3243A>G mutation. METHODS: In the context of a national inventory, the heteroplasmy levels of the m.3243A>G mutation were measured in leukocytes and urinary epithelial cells. The Newcastle Mitochondrial Disease Adult Scale score was determined and blood was drawn for measuring FGF21 concentration. Twenty-five of the included initial patients studied were then selected randomly for a follow-up study. RESULTS: This prognostic study included 99 adult carriers of the m.3243A>G mutation. Our analysis revealed a moderate, significant correlation between FGF21 concentration and disease severity (r = 0.49; p = <0.001). No significant correlations were found between disease severity and the heteroplasmy percentage determined in urinary epithelial cells or the heteroplasmy percentage determined in leukocytes. Weak but significant correlations were also found between FGF21 concentration and the severity of the myopathy (r = 0.38; p = <0.001) and between the concentration of FGF21 and the severity of the encephalopathy (r = 0.30; p = <0.001). Repeated measurements following 25 subjects for 2 years revealed no significant correlation between FGF21 concentration and disease progression. CONCLUSIONS: Measuring FGF21 concentration had little added value in monitoring and predicting the disease course in this specific patient group.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000000578

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 39

Metadata

Authors
Koene, S., de Laat, P., van Tienoven, D. H., Vriens, D., Brandt, A. M., Sweep, F. C. G. J., Rodenburg, R. J. T., Donders, A. R. T., Janssen, M. C. H., & Smeitink, J. A. M.
Venue
Neurology
Published
2014-07-08
Volume
83
Issue
2
Pages
125-133
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2142847844
Cited by
39
References
4
FWCI
1.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serum FGF21 levels in adult m.3243A>G carriers: Clinical implications. https://app.cochat.ai/papers/10.1212/wnl.0000000000000578
The paper
Koene, S., de Laat, P., van Tienoven, D. H., Vriens, D., Brandt, A. M., Sweep, F. C. G. J., Rodenburg, R. J. T., Donders, A. R. T., Janssen, M. C. H., & Smeitink, J. A. M. (2014). Serum FGF21 levels in adult m.3243A>G carriers: Clinical implications. Neurology. https://doi.org/10.1212/wnl.0000000000000578

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.